Katapult Holdings, Inc. - Common Stock KPLT 深 滬
已收盤 12-12 16:00:00 美东时间
7.13
+0.925
+14.91%
華盛通- 最 高9.23
- 今 開9.20
- 成交量 2076.80万股
- 最 低 7.00
- 昨 收 6.205
- 總市值 3258.05万
- 52周最高 24.34
- 市盈率 靜 --
- 換手率 454.49%
- 52周最低 5.08
- 委 比 -98.49%
- 總股本 456.95万
- 歷史最高 491.325
- 量 比 339.48
- 振 幅 35.94%
- 歷史最低 5.08
- 每 手 1
- 風險率 3.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Katapult Stock Jumps After Aaron's And CCF Agree To All Stock Merger
Katapult stock surges after agreeing to merge with Aaron's and CCF Holdings to create an omnichannel platform for non-prime consumers.
12-12 21:24
Market-Moving News for December 12th
AVGO: -6% | AVGO stock has given up its prior gain. Broadcom shares were trading higher after the company reported better-than-expected Q4 results and issued Q1 sales guidance above estimates. LULU: 12% |
12-12 20:19
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
12 Financials Stocks Moving In Monday's Pre-Market Session
Gainers AIFU (NASDAQ:AIFU) stock rose 12.0% to $4.35 during Monday's pre-marke...
11-10 20:07
Katapult Holdings Secures Fourth Limited Waiver Agreement
The latest update is out from Katapult Holdings ( ($KPLT) ). On October 20, 202...
10-21 05:57
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
Kiniksa Pharmaceuticals announced that the FDA granted Orphan Drug Designation to KPL-387 for treating pericarditis. KPL-387, a monoclonal antibody, inhibits IL-1α and IL-1β signaling. The company expects Phase 2/3 trial data in late 2026 and believes KPL-387 could offer a monthly subcutaneous self-injection treatment option. Orphan Drug Designation provides incentives for developing treatments for rare diseases.
10-17 12:00
Katapult Holdings Enters Limited Waiver To Loan Agreement; Waiver Of Existing Default Continued Until October 13, 2025
On September 29, 2025, Katapult Holdings, Inc. (the "Company") entered into the Limited Waiver (the "Second Limited Waiver") to our Amended and Restated Loan and Security Agreement, dated as of June 12, 2025 (as amended,
09-30 05:15
Katapult Receives Temporary Waiver on Loan Covenant Breach Until September 29, 2025
On September 15, 2025, Katapult Holdings, Inc. (the "Company") entered into the Limited Waiver (the "Limited Waiver") to our Amended and Restated Loan and Security Agreement, dated as of June 12, 2025 (as amended,
09-16 20:21
Goldman Sachs’ investment recommendation as Q4 approaches
Goldman Sachs investment strategists have identified three promising investment opportunities as we enter the final quarter of 2025: alternative asset managers, companies with high floating rate debt,...
09-09 03:15
